SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
View ORCID ProfileSintaroo Watanabe, View ORCID ProfileRokuro Hama
doi: https://doi.org/10.1101/2022.10.13.22281036
Sintaroo Watanabe
1Japan Marine United Corporation, Kure Shipyard, Kure, Japan
MD, PhDRokuro Hama
2Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Osaka, Japan
MD
Article usage
Posted December 22, 2022.
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
Sintaroo Watanabe, Rokuro Hama
medRxiv 2022.10.13.22281036; doi: https://doi.org/10.1101/2022.10.13.22281036
Subject Area
Subject Areas
- Addiction Medicine (423)
- Allergy and Immunology (746)
- Anesthesia (219)
- Cardiovascular Medicine (3232)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13243)
- Forensic Medicine (19)
- Gastroenterology (890)
- Genetic and Genomic Medicine (5064)
- Geriatric Medicine (470)
- Health Economics (773)
- Health Informatics (3185)
- Health Policy (1129)
- Hematology (423)
- HIV/AIDS (1005)
- Medical Education (468)
- Medical Ethics (125)
- Nephrology (513)
- Neurology (4807)
- Nursing (254)
- Nutrition (716)
- Oncology (2479)
- Ophthalmology (702)
- Orthopedics (279)
- Otolaryngology (337)
- Pain Medicine (320)
- Palliative Medicine (89)
- Pathology (529)
- Pediatrics (1279)
- Primary Care Research (550)
- Public and Global Health (7367)
- Radiology and Imaging (1668)
- Respiratory Medicine (969)
- Rheumatology (473)
- Sports Medicine (415)
- Surgery (534)
- Toxicology (69)
- Transplantation (232)
- Urology (199)